S&P 500   4,071.70 (-0.12%)
DOW   34,429.88 (+0.10%)
QQQ   292.55 (-0.40%)
AAPL   147.81 (-0.34%)
MSFT   255.02 (+0.13%)
META   123.49 (+2.53%)
GOOGL   100.44 (-0.54%)
AMZN   94.13 (-1.43%)
TSLA   194.86 (+0.08%)
NVDA   168.76 (-1.51%)
NIO   13.13 (+8.60%)
BABA   90.06 (+4.79%)
AMD   74.98 (-3.23%)
T   19.02 (-0.89%)
MU   54.68 (-1.46%)
CGC   4.29 (+9.16%)
F   13.86 (-1.56%)
GE   86.88 (+1.90%)
DIS   99.43 (+0.85%)
AMC   8.17 (+0.00%)
PYPL   74.66 (-4.93%)
PFE   50.91 (-0.33%)
NFLX   320.41 (+1.09%)
S&P 500   4,071.70 (-0.12%)
DOW   34,429.88 (+0.10%)
QQQ   292.55 (-0.40%)
AAPL   147.81 (-0.34%)
MSFT   255.02 (+0.13%)
META   123.49 (+2.53%)
GOOGL   100.44 (-0.54%)
AMZN   94.13 (-1.43%)
TSLA   194.86 (+0.08%)
NVDA   168.76 (-1.51%)
NIO   13.13 (+8.60%)
BABA   90.06 (+4.79%)
AMD   74.98 (-3.23%)
T   19.02 (-0.89%)
MU   54.68 (-1.46%)
CGC   4.29 (+9.16%)
F   13.86 (-1.56%)
GE   86.88 (+1.90%)
DIS   99.43 (+0.85%)
AMC   8.17 (+0.00%)
PYPL   74.66 (-4.93%)
PFE   50.91 (-0.33%)
NFLX   320.41 (+1.09%)
S&P 500   4,071.70 (-0.12%)
DOW   34,429.88 (+0.10%)
QQQ   292.55 (-0.40%)
AAPL   147.81 (-0.34%)
MSFT   255.02 (+0.13%)
META   123.49 (+2.53%)
GOOGL   100.44 (-0.54%)
AMZN   94.13 (-1.43%)
TSLA   194.86 (+0.08%)
NVDA   168.76 (-1.51%)
NIO   13.13 (+8.60%)
BABA   90.06 (+4.79%)
AMD   74.98 (-3.23%)
T   19.02 (-0.89%)
MU   54.68 (-1.46%)
CGC   4.29 (+9.16%)
F   13.86 (-1.56%)
GE   86.88 (+1.90%)
DIS   99.43 (+0.85%)
AMC   8.17 (+0.00%)
PYPL   74.66 (-4.93%)
PFE   50.91 (-0.33%)
NFLX   320.41 (+1.09%)
S&P 500   4,071.70 (-0.12%)
DOW   34,429.88 (+0.10%)
QQQ   292.55 (-0.40%)
AAPL   147.81 (-0.34%)
MSFT   255.02 (+0.13%)
META   123.49 (+2.53%)
GOOGL   100.44 (-0.54%)
AMZN   94.13 (-1.43%)
TSLA   194.86 (+0.08%)
NVDA   168.76 (-1.51%)
NIO   13.13 (+8.60%)
BABA   90.06 (+4.79%)
AMD   74.98 (-3.23%)
T   19.02 (-0.89%)
MU   54.68 (-1.46%)
CGC   4.29 (+9.16%)
F   13.86 (-1.56%)
GE   86.88 (+1.90%)
DIS   99.43 (+0.85%)
AMC   8.17 (+0.00%)
PYPL   74.66 (-4.93%)
PFE   50.91 (-0.33%)
NFLX   320.41 (+1.09%)
TSE:IN

InMed Pharmaceuticals - IN Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
C$4.19
C$4.19
52-Week Range
N/A
Volume
17,035 shs
Average Volume
29,552 shs
Market Capitalization
C$33.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IN stock logo

About InMed Pharmaceuticals (TSE:IN) Stock

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Receive IN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IN Stock News Headlines

InMed Pharma Gains 9%
InMed Pharma to Consolidate Shares
InMed Pharma Names Michael Woudenberg As COO
InMed CFO steps down, interim CFO appointed
InMed Announces Management Changes
See More Headlines

Receive IN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$574,677.00
Book Value
C$0.76 per share

Miscellaneous

Free Float
N/A
Market Cap
C$33.73 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Eric A. Adams (Age 58)
    Pres, CEO & Director
    Comp: $488.44k
  • Ms. Alexandra Diane-Janet Mancini (Age 69)
    Sr. VP of Clinical & Regulatory Affairs
    Comp: $337.13k
  • Dr. Sazzad Hossain M.Sc. (Age 64)
    Ph.D., Co-Founder
  • Ms. Brenda Edwards C.M.A.
    CPA, Interim Chief Financial Officer
  • Mr. Michael Woudenberg P.Eng. (Age 55)
    Chief Operating Officer
  • Colin Clancy
    Sr. Director of Investor Relations
  • Mr. Jerry P. Griffin
    VP of Sales & Marketing
  • Dr. Eric Chih-Hsien Hsu (Age 52)
    Sr. VP of Preclinical R&D
  • Dr. Shane A. Johnson Ph.D.
    Sr. VP & GM of BayMedica
  • Dr. Ado Muhammad
    Sr. Consultant of Medical Affairs













IN Stock - Frequently Asked Questions

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include OrganiGram (OGI), Aurora Cannabis (ACB), Canopy Growth (WEED), Baidu (BIDU), Cara Therapeutics (CARA), Copper Mountain Mining (CMMC), Corbus Pharmaceuticals (CRBP), HEXO (HEXO), InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU).

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN."

How do I buy shares of InMed Pharmaceuticals?

Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How much money does InMed Pharmaceuticals make?

InMed Pharmaceuticals (TSE:IN) has a market capitalization of C$0.00 and generates C$574,677.00 in revenue each year.

How can I contact InMed Pharmaceuticals?

The official website for the company is www.inmedpharma.com. The company can be reached via phone at 604-669-7207.

This page (TSE:IN) was last updated on 12/2/2022 by MarketBeat.com Staff